Neuroplastizität bei der Parkinson-Krankheit
Plastizität motorischer Systeme im Frühstadium der Parkinson-Krankheit
The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI), from Dr. Noam Harel's protocol IRB# STUDY00008096, and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. The TMS experiment will use a Magstim Bistimn 2002 transcranial magnetic stimulation (TMS) unit and standard figure-of-eight coil (70 mm diameter) to deliver stimulation on the surface of the scalp. Stimulation will be delivered using either a single pulse or with a paired-pulse protocol (two stimuli, through the same TMS coil at inter-stimulus intervals of 50 or 80 ms). All surface EMG signals will be pre-amplified within the sensor and sent wirelessly via blue-tooth connection to a Delsys data collection system. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function will used to assess behavioral status at baseline and 30-36 months later.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults diagnosed with Parkinson's Disease (early diagnosis, currently untreated) and age- and sex-matched healthy controls
Beschreibung
Inclusion Criteria:
Participants with PD
- Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria
- Not receiving levodopa or dopamine agonist to treat PD (at baseline)
- Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls
- Age- (+/- 3 years) and sex-matched to participants with PD
- Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters
Exclusion Criteria:
- Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent
- History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment
- History of bipolar disorder, post-traumatic stress disorder or major depressive disorder
- Other significant neurological disorders that may affect participation or performance in the study
- Implanted DBS or other neurosurgeries to treat PD
- Pregnancy
Additional exclusion criteria for TMS experiments (note that individuals who are excluded from the TMS experiment still have the opportunity to participate in the other data collection sessions):
- History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury
- Recent history of frequent syncope (fainting) episodes in response to blood, emotional stress, or sensory triggers.
- Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator)
- Pacemaker or any implanted device
- History of surgery on blood vessels, brain, or heart
- Unexplained, recurring headaches or concussion within the last six months
- Severe hearing impairment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Early (untreated) Parkinson's Disease
Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria. |
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function |
|
Healthy Controls
Age- and sex-matched healthy controls. |
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in volume of Subthalamic Nucleus
Zeitfenster: Baseline, 30-36 months
|
The volume of the subthalamic nucleus is assessed using MRI and reported in millimeters cubed (mm^3). |
Baseline, 30-36 months
|
|
Change in fractional Anisotropy of Subthalamic Nucleus
Zeitfenster: Baseline, 30-36 months
|
Fractional anisotropy, measured using MRI, is a unit-less value between zero and one that describes the degree of anisotropy of water diffusion in a specified brain area. Higher values indicate a greater degree of anisotropy, while a score of zero indicates isotropic diffusion. |
Baseline, 30-36 months
|
|
Change in cortico-STN Connectivity
Zeitfenster: Baseline, 30-36 months
|
Cortico-Subthalamic nucleus connectivity is measured using MRI and reported as a z score (unitless). |
Baseline, 30-36 months
|
|
Change in paired Associative Stimulation-Motor Evoked Potential (PAS-MEP)
Zeitfenster: Baseline, 30-36 months
|
Motor evoked potential is measured as the amplitude of change in target muscle electrical activity following transcranial magnetic stimulation (TMS) and reported in units of millivolts (mV). |
Baseline, 30-36 months
|
|
Change in Mattis Dementia Rating Scale 2 (DRS-2)
Zeitfenster: Baseline, 30-36 months
|
The DRS-2 consists of 24 items, rated on a scale from 0 to 6. Item scores are combined into five subscales: attention (8 items), initiation/perseveration (11 items), construction (6 items), conceptualization ( 6 items), and memory (5 items). These five subscale scores are summed to calculate a total score ranging from from 0 to 144 points, with lower scores indicating worse performance due to dementia. |
Baseline, 30-36 months
|
|
Change in Rey Complex Figure and Matrix Reasoning of the Wechsler Adult Intelligence Scale - IV
Zeitfenster: Baseline, 30-36 months
|
Measure of visuospatial construction, memory and reasoning. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Stroop Color Word Test
Zeitfenster: Baseline, 30-36 months
|
Measure of response inhibition, selective attention and processing. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Wisconsin Card Sorting Test
Zeitfenster: Baseline, 30-36 months
|
Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Subtest
Zeitfenster: Baseline, 30-36 months
|
Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Brief Visuospatial Memory Test - Revised (BVMT-R)
Zeitfenster: Baseline, 30-36 months
|
Measure of non-verbal (visuospatial) learning and memory abilities. Scaled score based on age norms. |
Baseline, 30-36 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Synucleinopathien
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Neurodegenerative Krankheiten
- Bewegungsstörungen
- Parkinsonsche Störungen
- Erkrankungen der Basalganglien
- Parkinson Krankheit
- Untersuchungstechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Diagnostische Bildgebung
- Diagnosetechniken, neurologisch
- Neuroimaging
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NEUR-2019-28388
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .